Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year […]
Research analysts at StockNews.com assumed coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) in a research note issued on Thursday. The firm set a “hold” rating on the biotechnology company’s stock. Other analysts have also recently issued research reports about the stock. Jefferies Financial Group upgraded shares of BioCryst Pharmaceuticals from a […]
GW&K Investment Management LLC increased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 50.8% in the first quarter, Holdings Channel.com reports. The firm owned 2,603,931 shares of the biotechnology company’s stock after acquiring an additional 876,844 shares during the period. GW&K Investment Management LLC’s holdings in BioCryst Pharmaceuticals were worth $21,717,000 at […]
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) – Equities researchers at HC Wainwright decreased their FY2026 earnings estimates for shares of BioCryst Pharmaceuticals in a research report issued to clients and investors on Friday, August 4th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will post earnings per share of $0.63 for […]
Jefferies Financial Group upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) from a hold rating to a buy rating in a report released on Friday morning, Marketbeat reports. They currently have $11.00 price objective on the biotechnology company’s stock. Several other research firms have also issued reports on BCRX. Needham & Company LLC reiterated […]